Compare Jones Lang LaSalle Inc (JLL) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs McKesson Corporation — how do they compare? Jones Lang LaSalle Inc trades at $300.42 (market cap $13.95B), while McKesson Corporation trades at $936.87 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 7.8× Jones Lang LaSalle Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| JLL | MCK | |
|---|---|---|
Market Cap | $13.95B | $108.46B |
Volume | 457,462 | 712,607 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $995.69 |
52-Week Low | $280.16 | $725.17 |
Enterprise Value | $16.71B | $115.00B |
Typical Hold Time | — | 74 Days |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $299.99, up 1.12% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $26.12B in 2025, and net income improved to $792.10M. Analyst consensus is bullish with a $450.50 price target, though technical indicators show resistance near $300.
JLL presents a compelling growth opportunity with improving profitability and a reasonable valuation (P/E 14.54). Risks include market volatility and execution challenges in real estate services. The stock's upside potential is supported by analyst optimism and strong cash flow trends, but investors should monitor Q3 earnings for confirmation of growth trajectory.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
